![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Clears Xavant Tech’s Pain Relief Neuromod
FDA Clears Xavant Tech’s Pain Relief Neuromod
![Green_Light.gif](https://www.fdanews.com/ext/resources/test/Device_Images5/Green_Light.gif?t=1625610540&width=430)
August 4, 2017
Xavant Technology announced FDA clearance for its Stimpod non-invasive pain relief neuromodulation device.
The device treats chronic, post-surgical and post-traumatic acute pain through a hybrid pulsed radio frequency waveform. The system uses nerve-locating technology and nerve mapping to track and assess treatment progress.
The South African company said it will use Bell Medical as its distributor for the device in the United States and Canada.
Upcoming Events
-
21Oct